However, the compound has been tested in patients with advanced CML, acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes because it has been found to successfully inhibit the T315I mutated form of BCR-ABL, which is resistant to imatinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.